CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
Vasopressin +1 moredrug
Likely dose
Vasopressin 250mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00886262
NCT00886262N/ACompleted
CompareCT.gov

Low Dose Vasopressin for Renal Protection During Liver Transplantation

Medical University of South Carolina·interventional·Posted Apr 22, 2009·Updated Oct 17, 2018

In Brief

A clinical study evaluating Vasopressin and Normal saline placebo for Liver Failure. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study is evaluate the medication vasopressin for its ability to preserve kidney function in patients undergoing liver transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Failure
CountriesUnited States
CollaboratorsEmory University

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 22, 2009
Enrollment StartJul 1, 2007
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 17.2 years ago

Interventions

Vasopressindrug

Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed

Normal saline placebodrug

Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter